{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T01:51:31Z","timestamp":1785030691566,"version":"3.55.0"},"reference-count":110,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have been approved for the treatment of many cancers, either in adjuvant or metastatic settings. Regarding safety, endocrine adverse events (AEs) are some of the most common AEs in ICI-treated patients, with thyroid dysfunction and hypophysitis being the most frequent disorders. However, there are also some rare and very rare immune-related (ir) endocrine complications (incidence between \u22651\/10,000 to &lt;1\/1000 and &lt;1\/10,000, respectively, according to the established classification) that have been reported in isolated case reports, with limited data about their management. In this systematic review, we summarize all published cases with primary adrenal insufficiency, central diabetes insipidus, primary hypoparathyroidism, lipodystrophy, osteoporosis, hypergonadotrophic hypogonadism, or Cushing disease and discuss their diagnostic and therapeutic approaches as well as the current knowledge on their pathophysiology. In these ICI-treated cancer patients, the presentation of symptoms unrelated to their underlying malignancy has led to further diagnostic tests, including hormonal profile and functional assays which subsequently confirmed endocrinopathy, while the assessment of autoantibodies was rarely available. In most of these cases, the exact pathogenesis remained unknown, and the endocrine dysfunction was permanent, requiring lifelong supplementation. Although endrocine irAEs are rare, physicians must be aware of these irAEs to recognize them on time and treat them appropriately.<\/jats:p>","DOI":"10.3390\/cancers15072016","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T07:05:25Z","timestamp":1679987125000},"page":"2016","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events"],"prefix":"10.3390","volume":"15","author":[{"given":"Chrysoula","family":"Mytareli","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, Unit of Endocrinology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-4004","authenticated-orcid":false,"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Medical Oncology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Karampela","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Endocrinology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-4066","authenticated-orcid":false,"given":"Petros","family":"Papalexis","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Endocrinology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Siampanopoulou","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Endocrinology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Lafioniatis","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Endocrinology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Benopoulou","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-2885","authenticated-orcid":false,"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Medical Oncology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-3617","authenticated-orcid":false,"given":"Anna","family":"Angelousi","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Unit of Endocrinology, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis","volume":"4","author":"Barry","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"51","author":"Andreescu","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"ref_8","unstructured":"(2022, October 01). Available online: https:\/\/health.ec.europa.eu\/system\/files\/2016-11\/smpc_guideline_rev2_en_0.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: A large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s40618-022-01845-z","article-title":"Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: A retrospective analysis using the FAERS","volume":"45","author":"Lu","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/pds.5108","article-title":"Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database","volume":"29","author":"Hasegawa","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J. Endocr. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.tjem.2017.05.007","article-title":"Nivolumab, a new immunomodulatory drug, a new adverse effect; adrenal crisis","volume":"17","author":"Akarca","year":"2017","journal-title":"Turk. J. Emerg. Med."},{"key":"ref_15","first-page":"5353202","article-title":"Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer","volume":"2019","author":"Agrawal","year":"2019","journal-title":"Case Rep. Neurol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): A case report and review of the literature","volume":"7","author":"Gunjur","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J. Endocr. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e231829","DOI":"10.1136\/bcr-2019-231829","article-title":"Nivolumab-induced adrenalitis","volume":"12","author":"Iqbal","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.anl.2019.05.009","article-title":"Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer","volume":"47","author":"Kagoshima","year":"2020","journal-title":"Auris Nasus Larynx"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/OP.20.00781","article-title":"Adrenal Insufficiency From Immune Checkpoint Inhibitors Masquerading as Sepsis","volume":"17","author":"Abdallah","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.36740\/WLek202002136","article-title":"An analysis of early morning acth levels in the first case of pembrolizumab-induced adrenalitis as a delayed immune-related event (dire)\u2014Case study","volume":"73","author":"Harsch","year":"2020","journal-title":"Wiad. Lek."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/10781552211038136","article-title":"Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?","volume":"28","author":"Ayhan","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"bvac036","DOI":"10.1210\/jendso\/bvac036","article-title":"It\u2019s Not Always SIAD: Immunotherapy-Triggered Endocrinopathies Enter the Field of Cancer-Related Hyponatremia","volume":"6","author":"Bischoff","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"ref_24","first-page":"16-0108","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107050","DOI":"10.1016\/j.intimp.2020.107050","article-title":"Reversible primary adrenal insufficiency related to anti-programmed cell-death 1 protein active immunotherapy: Insight into an unforeseen outcome of a rare immune-related adverse event","volume":"89","author":"Deligiorgi","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1159\/000507652","article-title":"Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature","volume":"13","author":"Salinas","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2021053363","DOI":"10.1542\/peds.2021-053363","article-title":"Polyendocrine Autoimmunity and Diabetic Ketoacidosis Following Anti-PD-1 and Interferon \u03b1","volume":"149","author":"Dasgupta","year":"2022","journal-title":"Pediatrics"},{"key":"ref_29","first-page":"e16933","article-title":"Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen","volume":"13","author":"Kashyap","year":"2021","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jemermed.2021.02.020","article-title":"Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies","volume":"61","author":"Knight","year":"2021","journal-title":"J. Emerg. Med."},{"key":"ref_32","first-page":"PA4853","article-title":"A case with a primary adrenal insufficiency secondary to nivolumab","volume":"48","author":"Coskun","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1188\/20.CJON.240-243","article-title":"Adrenal Insufficiency: Immune Checkpoint Inhibitors and Immune-Related Adverse Event Management","volume":"24","author":"Hobbs","year":"2020","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_34","first-page":"e8602","article-title":"A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary","volume":"12","author":"Gaballa","year":"2020","journal-title":"Cureus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4158\/ACCR-2017-0133","article-title":"Primary Adrenal Insufficiency from Immune Checkpoint Inhibitors","volume":"4","year":"2018","journal-title":"AACE Clin. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.clcc.2021.07.002","article-title":"Primary Adrenal Insufficiency and Acute Cardiomyopathy in a Patient With Colorectal Cancer Treated With Dual Immune Checkpoint Inhibitors","volume":"20","author":"Kojadinovic","year":"2021","journal-title":"Clin. Colorectal. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000491631","article-title":"Acute Kidney Injury after Pembrolizumab-Induced Adrenalitis and Adrenal Insufficiency","volume":"8","author":"Hanna","year":"2018","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1871530321666210708142815","article-title":"A Case of Cancer-Associated Hyponatraemia: Primary Adrenal Insufficiency Secondary to Nivolumab","volume":"22","author":"Galliazzo","year":"2022","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced Addison\u2019s disease: A rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2018-01836","article-title":"Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e223461","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ando.2018.03.008","article-title":"Autoimmune Addison\u2019s disease\u2014An update on pathogenesis","volume":"79","author":"Hellesen","year":"2018","journal-title":"Ann. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrendo.2011.245","article-title":"Autoimmune Addison disease: Pathophysiology and genetic complexity","volume":"8","author":"Mitchell","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMra1713301","article-title":"Autoimmune Polyendocrine Syndromes","volume":"378","author":"Husebye","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.bulcan.2019.02.003","article-title":"Immunotherapy-induced endocrinopathies: Insights from the 2018 French Endocrine Society Guidelines","volume":"106","author":"Castinetti","year":"2019","journal-title":"Bull. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: A prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1507\/endocrj.EJ20220831","article-title":"Changing the name of diabetes insipidus: A position statement of The Working Group for Renaming Diabetes Insipidus","volume":"69","author":"Arima","year":"2022","journal-title":"Endocr. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: A 10-year assessment","volume":"14","author":"Ippolito","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","article-title":"Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: A disproportionality analysis using the WHO adverse drug reaction database, VigiBase","volume":"69","author":"Bai","year":"2020","journal-title":"Endocrine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: A real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_52","first-page":"483","article-title":"Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy","volume":"64","author":"Brilli","year":"2020","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000521608","article-title":"Severe Hyponatremia Masking Central Diabetes Insipidus in a Patient with a Lung Adenocarcinoma","volume":"15","year":"2022","journal-title":"Case Rep Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.ccm.0000619648.08126.8f","article-title":"Diabetes Insipidus in Checkpoint Inhibitor Treatment and Acute Myeloid Leukemia","volume":"48","author":"Grami","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_57","first-page":"17-0146","article-title":"Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies","volume":"2018","author":"Gunawan","year":"2018","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2018.09.016","article-title":"Hypothalamitis and severe hypothalamic dysfunction associated with anti-programmed cell death ligand 1 antibody treatment","volume":"104","author":"Tshuma","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"582394","DOI":"10.3389\/fonc.2020.582394","article-title":"Case Report: Ipilimumab-Induced Panhypophysitis: An Infrequent Occurrence and Literature Review","volume":"10","author":"Barnabei","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106427","DOI":"10.1016\/j.intimp.2020.106427","article-title":"Central diabetes insipidus related to anti-programmed cell-death 1 protein active immunotherapy","volume":"83","author":"Deligiorgi","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/imt-2020-0334","article-title":"Anti-PD-1 treatment-induced immediate central diabetes insipidus: A case report","volume":"13","author":"Yu","year":"2021","journal-title":"Immunotherapy"},{"key":"ref_62","first-page":"20-0123","article-title":"Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis","volume":"2021","author":"Fosci","year":"2021","journal-title":"Endocrinol. Diabetes Metab. Case Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 Treatment Induced Central Diabetes Insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3892\/etm.2022.11709","article-title":"Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review","volume":"25","author":"Angelousi","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11102-021-01182-z","article-title":"Differences between immunotherapy-induced and primary hypophysitis-a multicenter retrospective study","volume":"25","author":"Amereller","year":"2022","journal-title":"Pituitary"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Barnabei, A., Corsello, A., Paragliola, R.M., Iannantuono, G.M., Falzone, L., Corsello, S.M., and Torino, F. (2022). Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle. Cancers, 14.","DOI":"10.3390\/cancers14041057"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41423-019-0232-2","article-title":"Hypothalamic expression of PD-L1: Does it mediate hypothalamitis?","volume":"16","author":"Iervasi","year":"2019","journal-title":"Cell Mol. Immunol. China"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41572-019-0103-2","article-title":"Diabetes insipidus","volume":"5","author":"Bichet","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Clinical practice. Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e000687","DOI":"10.1136\/jitc-2020-000687","article-title":"Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: Diagnosis and long-term follow-up","volume":"8","author":"Dadu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_72","first-page":"821","article-title":"Hypoparathyroidism: An Uncommon Complication Associated With Immune Checkpoint Inhibitor Therapy","volume":"Volume 4","author":"Li","year":"2020","journal-title":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am. J. Emerg. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report","volume":"14","author":"Umeguchi","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1210\/clinem\/dgaa092","article-title":"Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism","volume":"105","author":"Lupi","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.aace.2020.11.003","article-title":"Pembrolizumab-Associated Hypoparathyroidism: A Single Case Report","volume":"Volume 7","author":"Mahmood","year":"2021","journal-title":"AACE Clinical Case Reports"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10637-015-0243-5","article-title":"Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer","volume":"33","author":"Horinouchi","year":"2015","journal-title":"Investig. New. Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1530\/EC-19-0163","article-title":"Programmed death ligand 1 (PD-L1) expression in parathyroid tumors","volume":"8","author":"Pan","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2796.2009.02090.x","article-title":"Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I","volume":"265","author":"Husebye","year":"2009","journal-title":"J. Intern. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1713301","article-title":"Autoimmune Polyendocrine Syndromes","volume":"378","author":"Husebye","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: A Canadian and International Consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.autrev.2014.01.044","article-title":"Diagnosis and classification of autoimmune parathyroid disease","volume":"13","author":"Betterle","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrendo.2010.199","article-title":"Lipodystrophy: Pathophysiology and advances in treatment","volume":"7","author":"Fiorenza","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.4158\/ACCR-2019-0234","article-title":"A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin. Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_90","first-page":"1513","article-title":"Facial lipodystrophy after immunotherapy with Nivolumab","volume":"19","author":"Drexler","year":"2021","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/L19-0635","article-title":"Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade","volume":"172","author":"Eigentler","year":"2020","journal-title":"Ann. Intern. Med. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"965258","DOI":"10.3389\/fendo.2022.965258","article-title":"Immunoporosis: Role of immune system in the pathophysiology of different types of osteoporosis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ijc.33592","article-title":"Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis","volume":"149","author":"Filippini","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"100459","DOI":"10.1016\/j.jbo.2022.100459","article-title":"Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis","volume":"37","author":"Pantano","year":"2022","journal-title":"J. Bone Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/cas.13226","article-title":"Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"125705","DOI":"10.1155\/2013\/125705","article-title":"The Role of Inflammatory Cytokines, the RANKL\/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis","volume":"2013","author":"Weitzmann","year":"2013","journal-title":"Scientifica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"100276","DOI":"10.1016\/j.esmoop.2021.100276","article-title":"Checkpoint inhibitors, fertility, pregnancy, and sexual life: A systematic review","volume":"6","author":"Garutti","year":"2021","journal-title":"ESMO Open"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Opsomer","year":"2017","journal-title":"Ann. Oncol. Engl."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"101488","DOI":"10.1016\/j.eucr.2020.101488","article-title":"Onset of azoospermia in man treated with ipilimumab\/nivolumab for BRAF negative metastatic melanoma","volume":"Volume 34","author":"Rabinowitz","year":"2021","journal-title":"Urology Case Reports"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2021.04.031","article-title":"Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study","volume":"152","author":"Salzmann","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","article-title":"Association of Impaired Spermatogenesis With the Use of Immune Checkpoint Inhibitors in Patients With Metastatic Melanoma","volume":"6","author":"Scovell","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/OP.22.00469","article-title":"Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology","volume":"18","author":"Kim","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/CMR.0000000000000405","article-title":"Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination","volume":"27","author":"Lupu","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Shalit, A., Sarantis, P., Koustas, E., Trifylli, E.M., Matthaios, D., and Karamouzis, M.V. (2023). Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers, 15.","DOI":"10.3390\/cancers15020375"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:05:05Z","timestamp":1760123105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/7\/2016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":110,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cancers15072016"],"URL":"https:\/\/doi.org\/10.3390\/cancers15072016","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}